| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Afamin, Alpha-albumin, Alpha-Alb, AFM, ALB2, ALBA |
| Entrez GeneID | 173 |
| WB Predicted band size | 69.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This AFM antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 49-76 amino acids from the N-terminal region of human AFM. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是关于AFM(N-term)抗体的3篇参考文献示例，格式为文献名称、作者及摘要概括：
---
1. **"A monoclonal antibody targeting the N-terminal domain of AFM reveals its role in cellular adhesion"**
*Authors: Lee, J. et al.*
**摘要**：本研究开发了一种靶向AFM蛋白N端结构域的单克隆抗体，证实其通过阻断AFM与整合素的相互作用抑制癌细胞迁移，为肿瘤治疗提供潜在工具。
2. **"N-terminal specific AFM antibody enables precise detection of early-stage liver fibrosis"**
*Authors: Wang, Y. et al.*
**摘要**：通过制备高亲和力的AFM N端抗体，实现了对血清中低浓度AFM的灵敏检测，验证了其在肝纤维化早期诊断中的临床应用价值。
3. **"Structural mapping of AFM’s N-terminal epitope using antibody-guided atomic force microscopy"**
*Authors: Müller, A.D. et al.*
**摘要**：结合AFM N端抗体与原子力显微镜技术，解析了AFM蛋白N端在细胞膜表面的构象动态变化，揭示其机械信号传导机制。
---
*注：以上文献为示例性质，实际引用需根据具体研究内容检索真实数据库(如PubMed)。若需精准文献，建议提供AFM蛋白全称或相关研究领域。*
AFM (Afamin) is a secreted glycoprotein belonging to the albumin family, primarily synthesized in the liver and found in bodily fluids like blood plasma, cerebrospinal fluid, and ovarian follicular fluid. It functions as a carrier for hydrophobic molecules, including lipids and fat-soluble vitamins (e.g., vitamin E), and interacts with Wnt signaling proteins, suggesting roles in cellular growth, metabolism, and oxidative stress response. Dysregulation of AFM has been linked to metabolic disorders, neurodegenerative diseases, and cancers, making it a potential biomarker or therapeutic target.
The AFM (N-term) antibody specifically targets the N-terminal region of the protein, which is critical for its structural stability and ligand-binding activity. This antibody is typically generated using recombinant AFN-terminal fragments or synthetic peptides as immunogens. It enables the detection and quantification of AFM in research applications such as Western blotting, immunohistochemistry, and ELISA. By focusing on the N-terminal domain, the antibody helps study post-translational modifications, protein-protein interactions, and functional alterations in disease models. Its development supports ongoing investigations into AFM's role in pathologies like ovarian cancer, Alzheimer’s disease, and diabetes, offering insights into disease mechanisms and diagnostic potential.
×
